MedTrace Logo

Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC

NCT04322578 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2024-06-04

No results posted yet for this study

Summary

This study aims to explore the efficacy and safety of Crizotinb or Standard Chemotherapy in Met exon 14 skipping Advanced Non-small Cell Lung Cancer

Conditions

Interventions

DRUG

Crizotinib

Crizotinib 250mg po bid. Savolitinib 300mg po, qd.

DRUG

Pemetrexed

Pemetrexed, 500mg/m2, ivgtt erery 21day.

Sponsors & Collaborators

  • Hunan Province Tumor Hospital

    lead OTHER

Principal Investigators

  • Yongchang Zhang, MD · Hunan Cancer Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-24
Primary Completion
2025-03-24
Completion
2026-03-24

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04322578 on ClinicalTrials.gov